The ligand-dependent nuclear receptor peroxisome proliferatoractivated receptor-␥ (PPAR␥) regulates the differentiation of several tissues and cell types. PPAR␥ was recently determined to be essential for murine placental development and differentiation. We therefore assessed the influence of PPAR␥ on differentiation of human placental trophoblasts. We initially used immunohistochemistry to examine term human placentas for PPAR␥ expression and found that PPAR␥ is present in syncytiotrophoblasts and cytotrophoblasts in placental villi. We correlated the expression of PPAR␥ with differentiation of primary human trophoblasts and found that 8-bromo-cAMP, a known enhancer of trophoblast differentiation, stimulates PPAR␥ activity, but has no effect on PPAR␥ expression. We demonstrated that the PPAR␥ ligand 15-deoxy-⌬ 12,14 -prostaglandin J 2 (15⌬PGJ 2 ) and the thiazolidinedione troglitazone stimulate PPAR␥ activity in the trophoblast cell line BeWo. Importantly, whereas exposure of cultured primary trophoblasts to troglitazone enhances biochemical and morphological trophoblast differentiation, 15⌬PGJ 2 diminishes trophoblast differentiation. Furthermore, 15⌬PGJ 2 , but not troglitazone, up-regulates p53 expression and promotes trophoblast apoptosis. These data indicate that PPAR␥ is expressed in human placental trophoblasts, and that ligand-specific activation of PPAR␥ results in opposing effects on trophoblast differentiation. Our results suggest that PPAR␥ plays an important role in placental differentiation during human pregnancy. (J Clin Endocrinol Metab 85: 3874 -3881, 2000) 
the fetus exchanges oxygen, nutrients, and waste products with the maternal circulation through the placenta. The syncytiotrophoblast is a multinucleated, terminally differentiated cell mass that covers the surface of placental villi and is therefore in direct contact with maternal blood. Subjacent to the syncytiotrophoblasts are mitotically active cytotrophoblasts that provide a stem cell population capable of terminal differentiation into syncytiotrophoblast through a process of cell-cell fusion. The differentiation of cytotrophoblasts into syncytiotrophoblasts is essential for placental function and, therefore, fetal development.
Peroxisome proliferator-activated receptors (PPARs) are members of the steroid receptor superfamily of nuclear receptors. They consist of three subtypes: PPAR␣, PPAR␥, and PPAR␦ (1) . Each subtype has a distinct tissue distribution, with PPAR␣ present in high levels in the kidney, heart, muscle, and liver (2, 3) , whereas PPAR␦ is present in most tissues (2, 4) . PPAR␥, in turn, is expressed predominantly in adipose tissue (2, (5) (6) (7) as well as in monocytes, tissue macrophages (8, 9) , and placenta (10) . Several naturally occurring ligands for PPAR␥ have been identified, including fatty acids (11) , oxidized low density lipoprotein derivatives (12) , and the PG metabolite 15-deoxy-⌬ 12, 14 -prostaglandin J 2 (15⌬PGJ 2 ) (13, 14) . In addition, the antidiabetic thiazolidinedione drugs function as ligands for PPAR␥ (13, 15, 16) . PPAR␥ plays a role in the differentiation of several cell types, including preadipocytes (5, 13, 17, 18) , myoblasts (19) , and monocytes (8) , and in the terminal differentiation of breast cancer (20) and liposarcoma cells (7) . Importantly, mice deficient in PPAR␥ exhibit abnormal placental development and trophoblast differentiation (21, 22) . Specifically, the placentas of PPAR␥-deficient embryos have a labyrinth that forms an excessively thick layer surrounding the chorionic villi and retains the immature characteristics of the early labyrinthine parenchyma instead of maturing into a normal trilaminar epithelial barrier (21) . These placentas also exhibit anomalous placental vasculature. These developmental defects result in embryonic death on embryonic day 10, when maintenance of fetal metabolism transitions from the yolk sac to the labyrinthine placenta. These data underscore the role of PPAR␥ in terminal differentiation of murine placental trophoblasts.
Although PPAR␥ is essential for normal placental development and trophoblast differentiation in mice, the role of PPAR␥ in the human placenta is unknown. We hypothesized that PPAR␥ plays an important role in human trophoblast differentiation. Our data demonstrate that PPAR␥ is expressed in both cytotrophoblast and syncytiotrophoblast of human trophoblast, and that 8-bromo-cAMP (8-Br-cAMP), a known inducer of trophoblast differentiation, enhances PPAR␥ activity. Importantly, we discovered that two types of PPAR␥ ligands that stimulate PPAR␥ activity in trophoblasts have opposing effects on human trophoblasts, one promoting differentiation and the other hindering differentiation and promoting apoptosis.
Materials and Methods Immunohistochemistry
Our study was approved by the human studies committee of Washington University (St. Louis, MO). Placentas from term (Ͼ37 weeks) uncomplicated pregnancies were collected immediately after delivery, fixed for 1 h in 10% neutral buffered formalin, and embedded in paraffin. Five-micron sections were deparaffinized in xylene and rehydrated in an ethanol gradient. Endogenous peroxidase activity was quenched by incubating the specimens in 3% H 2 O 2 in methanol for 30 min. After equilibrating for 5 min in distilled water, the samples were heated at maximum power in a microwave for 10 min. The slides were washed, blocked for 30 min with normal horse serum, and incubated for 2 h at room temperature with monoclonal mouse antihuman PPAR␥ (anti-PPAR␥ E-8, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or with an isotype-matched control antibody supplied in the immunostaining kit (Santa Cruz Biotechnology, Inc.). In some experiments, the anti-PPAR␥ antibody was preincubated for 30 min at room temperature with a blocking peptide specific for the anti-PPAR␥ antibody (Santa Cruz Biotechnology, Inc.), at approximately 30-fold excess relative to the antigenbinding sites of the antibody. After washes, the slides were incubated for 30 min with a biotinylated antimouse secondary antibody (Vector Laboratories, Inc., Burlingame, CA), followed by 30-min incubation with avidin/biotin-horseradish peroxidase complex (Vector Laboratories, Inc.) and 3-min incubation with diaminobenzidene (Zymed Laboratories, Inc., South San Francisco, CA). The slides were rinsed and counterstained with Mayer's hematoxylin (Sigma, St. Louis, MO), dehydrated in ethanol, cleared with xylene, and mounted with glass coverslips using Histomount (Zymed Laboratories, Inc.). Paraffin sections were stained for cyclin E as described above, except that monoclonal anticyclin E (Novocastra Laboratories, Newcastle upon Tyne, UK) was used as the primary antibody, Vector NovaRED (Vector Laboratories, Inc.) was used as the substrate, and the sections were not counterstained.
Cell cultures
Primary human cytotrophoblasts were prepared from normal term human placentas using the trypsin-deoxyribonuclease-dispase/Percoll method as described by Kliman (23) with previously published modifications (24) . Cultures were plated at a density of 350,000 cells/cm 2 and maintained in Earl's medium 199 containing 10% FBS (HyClone Laboratories, Inc., Logan, UT), 20 mmol/L HEPES (pH 7.4), 0.5 mmol/L l-glutamine (Sigma), penicillin (10 U/mL), streptomycin (10 g/mL), and fungizone (0.25 g/mL). In some experiments trophoblasts were grown in Ham's/Waymouth's medium (H/W) composed of equal volumes of Ham's F-12 medium and Waymouth's medium, supplemented as described above for medium 199. All cultures were maintained at 37 C in a 5% CO 2 
Immunofluorescence and TUNEL
Primary trophoblasts were stained with antidesmosomal and antinuclear antibodies as previously described (24) . Briefly, cells were fixed with Ϫ20 C methanol for 20 min. After rinsing in phosphate-buffered saline (PBS), the cells were blocked with 2% goat serum in staining buffer (PBS/0.2% BSA/0.02% sodium azide) for 35 min in a humidified chamber at 37 C, then incubated for 35 min at 37 C with a cocktail of monoclonal mouse antihuman desmosome antibody (Sigma) and human antinuclear antibody (Antibodies, Inc., Davis, CA), diluted in staining buffer. The plates were washed, then incubated with a cocktail of fluorescein isothiocyanate-goat antimouse IgG (Fab-specific, Sigma) and tetramethylrhodamine B isothiocyanate-goat antihuman IgG (Sigma) for an additional 35 min at 37 C. After washing, the cells were mounted with Gel/Mount (Biomeda, Foster City, CA) and viewed by epifluorescence using an MRC 1024 confocal microscope and LaserSharp version 3.2 software (Bio-Rad Laboratories, Inc., Hercules, CA). A syncytium was defined as three or more nuclei in the same cytoplasm without intervening surface desmosomal membrane staining. Quantitation was performed by counting the number of syncytia per random field and the number of nuclei per syncytium. Syncytia were counted only when they were entirely contained within the field. At least four fields were counted. Statistical analysis was performed using unpaired Student's t test with StatView 4.0 software (Abacus Concepts, Berkeley, CA).
For terminal deoxynucleotidyltransferase-mediated deoxy-UTP nick end labeling (TUNEL) staining, cells were dried over a flame, and fixed in 4% formalin for 10 min. Endogenous peroxidase was quenched with 3% H 2 O 2 , and cells were washed with PBS. The ApopTag kit (Oncor, Gaithersburg, MD) was used for TUNEL staining. Briefly, cells were incubated in an equilibration buffer for 10 min and then in a 37 C humidified chamber for 1 h with terminal deoxynucleotidyltransferase and deoxy-UTP-digoxigenin. The reaction was stopped, and cells were washed and incubated with antidigoxigenin peroxidase solution, colorized with amino ethylcarbazole (Vector Laboratories, Inc.), counterstained with hematoxylin, and examined by brightfield microscopy. The apoptotic index was defined as the number of TUNEL-positive cells divided by the total number of cells counted.
Western blotting and densitometric analysis
The plates were rinsed with PBS and lysed with 250 L cold lysis buffer (1% Nonidet P-40, 0.5% deoxycholate, and 0.1% SDS in PBS) containing a protease inhibitor cocktail (Sigma). The plates were scraped, and the lysate was sonicated three times for 10 s each time on ice with a Sonic Dismembrator 50 (Fisher, Pittsburgh, PA). The lysates were centrifuged, and 30 g protein/lane were separated on 10% SDS-PAGE gels at 80 V for 3 h. After separation, the proteins were transferred to polyvinylidene difluoride membranes (Immobilon-P, Millipore Corp., Bedford, MA) for 3 h, 4 C at 400 mA. The blot was then rinsed briefly with 0.15 mol/L NaCl and 10 mmol/L Tris-HCl, pH 8.0, containing 0.2% Tween-20, blocked for 30 min with 5% powdered milk in 0.15 mol/L NaCl and 10 mmol/L Tris-HCl, pH 8.0, containing 0.2% Tween-20, then incubated overnight at 4 C with primary antibody (mouse monoclonal anti-PPAR␥ or mouse monoclonal anti-p53, Santa Cruz Biotechnology, Inc.). The blot was incubated for 1 h with horseradish peroxidase-conjugated goat antimouse IgG secondary antibody (Santa Cruz Biotechnology, Inc.), washed, and processed for luminescence using the Amersham Pharmacia Biotech ECL kit (Amersham Pharmacia Biotech, Arlington Heights, IL). Densitometric analysis was performed using a Molecular Dynamics, Inc. PD densitometer and ImageQuant version 3.3 software (Molecular Dynamics, Inc., Sunnyvale, CA).
hCG concentration determination
Culture supernatants were assayed for hCG using a microparticle immunoassay (Abbott Laboratories, Abbott Park, IL). Values represent hCG secreted per 24-h interval, normalized to total cellular DNA and expressed as the mean Ϯ sd of duplicate samples.
Transient transfection and PPRE reporter assay
The PPREx3-Luc reporter plasmid was constructed by cloning three copies of the acyl-coenzyme A oxidase promoter PPAR response element (PPRE) plus eight nucleotides of the 5Ј-flanking sequence (AGGG-GACCAGGACAAAGGTCA, where the PPRE DR-1 sequence is underlined) (26 -28) into the BamHI polylinker site in a P36-Luc reporter (29) (gift from Dr. Stuart Adler, Washington University, St. Louis, MO) upstream of the firefly luciferase gene. The use of three PPRE elements in the reporter constructs had been previously described (13) and gives a more robust response than a single PPRE and thus a more accurate quantitation of PPAR␥ activity. Placental trophoblasts or BeWo cells were plated 1 day before transfection. Transfection was performed according to the calcium-phosphate precipitation method, previously described (30, 31), using 2.0 g of either PPREx3-Luc or the parent P36 plasmid, 2.0 g salmon sperm DNA, and 0.02 g Rous sarcoma virus-␤-galactosidase reporter construct (to normalize for cell viability and transfection efficiency). The luciferase assay was performed 40 -48 h after the transfection. Cells were lysed in a lysis buffer that contains 50 mmol/L Tris-2-[N-morpholino]ethanesulfonic acid (pH 7.8), 1 mmol/L dithiothreitol, and 1% Triton X-100. Lysates were assayed for luciferase using a luminometer (Monolight 2010, Analytical Luminescence Laboratory, San Diego, CA) and for ␤-galactosidase using a plate reader (Anthos htIII, Salzburg, Austria). All experiments were performed in duplicate and repeated at least three times. Results (mean Ϯ sd) were expressed as the fold increase in relative luciferase units, corrected to ␤-galactosidase, and compared to unstimulated cultures.
Results

PPAR␥ is expressed in human villous trophoblasts
We first sought to examine the expression of PPAR␥ in the human placenta. For this purpose we stained sections of placentas derived from women after uncomplicated term deliveries. As shown in Fig. 1, a and b , syncytiotrophoblast nuclei strongly express PPAR␥. Because cytotrophoblasts also appeared to express PPAR␥ (Fig. 1a) , we stained serial sections for either PPAR␥ or cyclin E, which is expressed in placental cytotrophoblasts, but not in the syncytiotrophoblast or villous core cells (32) . Indeed, cell nuclei that stained positively for cyclin E were also positive for PPAR␥ (Fig. 1,  b and c), demonstrating that cytotrophoblasts express PPAR␥. PPAR␥ was also expressed in the nuclei of endothelial cells in villous blood vessels (Fig. 1a) and in the nuclei of Hofbauer cells (data not shown), but not in other villous core cells. The specificity of the staining was confirmed in control stains in which staining was performed in the presence of an excess of PPAR␥-blocking peptide (compare Fig.  1, d and e) , and also in stains in which the primary antibody was omitted (Fig. 1f) . In addition, no staining was observed when an isotype-matched control antibody was used as the primary antibody (data not shown).
Induction of trophoblast differentiation does not alter PPAR␥ expression
Because PPAR␥ is expressed in both cytotrophoblast and syncytiotrophoblast, we sought to determine whether its expression is altered during trophoblast differentiation. Trophoblasts were cultured in the presence or absence of 1 mmol/L 8-Br-cAMP, a known stimulant of cytotrophoblast differentiation into syncytiotrophoblast (25, 33) . As shown in Fig. 2A, 8 -Br-cAMP stimulated cytotrophoblast differentiation, demonstrated by the increase in hCG secretion during 72 h of culture. However, trophoblast differentiation was not associated with enhanced PPAR␥ expression (Fig. 2B) . Interestingly, culturing trophoblasts in H/W medium, which hinders cytotrophoblast differentiation (34) (Fig. 2A) led to a corresponding diminution of PPAR␥ expression (5-fold by 72 h; Fig. 2B ). These data indicate that although PPAR␥ expression is maximal at 24 h of standard culture and cannot be further enhanced by stimulation of differentiation, hindered differentiation is associated with diminished PPAR␥ expression. We further determined whether PPAR␥ activity changes during trophoblast differentiation. For this purpose we transfected primary trophoblasts with a PPREx3-Luc reporter construct that contained a luciferase gene under the control of three PPRE sites inserted upstream of luciferase (Fig. 2C) . To control for nonspecific increases in transcription due to cellular activation, we transfected duplicate cultures with the reporter plasmid lacking the PPRE sites. We found that 8-Br-cAMP induced an 8-to 10-fold increase in intrinsic PPAR␥ activity, and that this effect was trophoblast specific, because the addition of 8-Br-cAMP did not enhance PPREx3-Luc reporter transcription in CV-1 cells (Fig. 2C) . Addition of 8-Br-cAMP resulted in minimal (2-fold) stimulation of the P36 control reporter in either primary trophoblasts or CV-1 cells (Fig. 2C) , suggesting a nonspecific effect by 8-Br-cAMP. Taken together, these data demonstrate that 8-Br-cAMP induces a PPRE-specific increase in transcriptional activity in primary trophoblasts, indicative of increased intrinsic PPAR␥ activity. Thus, although intracellular levels of PPAR␥ remain unchanged, the activity of PPAR␥ increases when trophoblasts are stimulated to differentiate by 8-Br-cAMP.
PPAR␥ ligands exhibit opposing effects on trophoblast differentiation
To determine whether activation of PPAR␥ alters the differentiation of human cytotrophoblasts, we cultured trophoblasts in the presence or absence of troglitazone or 15⌬PGJ 2 . We first established that both ligands stimulate PPAR␥ activity using the choriocarcinoma cell line BeWo. As shown in Fig. 3A , both ligands enhanced luciferase expression from the PPREx3-Luc reporter construct, reflecting PPAR␥ activation. Importantly, primary trophoblasts incubated in the presence of troglitazone exhibited a 2-to 5-fold increase in hCG secretion relative to control cultures at 72 h (Fig. 3B) , indicating enhancement of biochemical differentiation of cytotrophoblasts. In contrast, incubation in the presence of 15⌬PGJ 2 diminished hCG production from trophoblasts. To eliminate the possibility that a lower concentration of either ligand might have a different effect on trophoblast differentiation, we titrated troglitazone or 15⌬PGJ 2 in trophoblast cultures. As shown in Fig. 3C , troglitazone stimulated hCG secretion at 1.0 and 10 mol/L, whereas 15⌬PGJ 2 led to a concentration-dependent decrease in hCG secretion at the same concentrations. Taken together, these data indicate that the disparate effects of the two ligands on trophoblast differentiation were maintained even at a lower concentration. Interestingly, addition of the PPAR␥ antagonist BADGE (35) led to a decrease in both basal and troglitazone-induced hCG production (Fig. 3D) , supporting the idea that prodifferentiation PPAR␥ ligands may predominate in native trophoblast cultures. In addition, when trophoblasts were cultured in the presence of both troglitazone and 8-Br-cAMP, an additive increase in hCG secretion was observed compared to that with either substance alone, whereas cultures exposed simultaneously to 15DPGJ 2 and 8-Br-cAMP showed only a slight increase in hCG secretion relative to those given 15DPGJ 2 alone (data not shown). These results are consistent with the induction of an endogenous ligand by 8-Br-cAMP and indicate that the effect of 15DPGJ 2 is dominant over that of 8-Br-cAMP.
To substantiate the effects of troglitazone and 15⌬PGJ 2 on trophoblast differentiation, we examined syncytium formation as an indicator of morphological differentiation. As shown in Fig. 4 , in control cultures most trophoblasts were present as mononucleated cytotrophoblasts at 24 h (1.5 Ϯ 0.6 syncytia/field, 4.3 Ϯ 1.0 nuclei/syncytium), with more abundant, larger syncytia at 48 h (4.3 Ϯ 1.0 syncytia/field; P ϭ 0.001 vs. 24 h; and 11.6 Ϯ 8.4 nuclei/syncytium, P ϭ 0.04 vs. 24 h). Syncytium formation was accelerated in cultures containing troglitazone, yielding 5.8 Ϯ 2.5 syncytia/field (P ϭ 0.01 vs. 24-h control) with 6.9 Ϯ 3.1 nuclei/syncytium at 24 h. Syncytia were larger and more abundant at 48 h, such that each field usually consisted of 2-3 large syncytia (Ͼ15 nuclei/syncytium) that extended beyond the edges of the field, making quantitation of random fields impossible. By 72 h, both control and troglitazone-containing cultures consisted of these large syncytia and were indistinguishable from each other. In contrast, trophoblasts cultured in the presence of 15⌬PGJ 2 showed little syncytium formation throughout the culture period, yielding 0.8 Ϯ 1.3, 1.3 Ϯ 1.4, and 0.8 Ϯ 1.2 syncytia at 24, 48, and 72 h, respectively (P ϭ NS vs. control at 24, P ϭ 0.001 vs. control at 48 h, and qualitatively markedly different at 72 h). Furthermore, each syncytium contained only 3-4 nuclei. Therefore, we concluded that troglitazone enhances biochemical and morphological differentiation of cytotrophoblasts, whereas 15⌬PGJ 2 abrogates cytotrophoblast differentiation.
15⌬PGJ 2 stimulates trophoblast apoptosis
Trophoblasts cultured in the presence of 15⌬PGJ 2 exhibit small, dense nuclei and nuclear fragments (Fig. 4, 15⌬PGJ 2 ) , suggesting that the trophoblasts may be undergoing apoptosis. Because of this observation and because 15⌬PGJ 2 has been shown to induce apoptosis in the JEG-3 cell line (36) and in other cells (9, 37, 38), we evaluated whether 15⌬PGJ 2 induces apoptosis in primary human trophoblasts. As shown in Fig. 5A , 15⌬PGJ 2 enhanced trophoblast apoptosis (apoptotic index, 14.3%) relative to the control (apoptotic index, 4.3%), determined by the TUNEL technique. There was no increase in apoptosis when trophoblasts were incubated with troglitazone (apoptotic index, 3.2%). Because it is known that diverse apoptotic stimuli induce the accumulation and activation of the tumor suppressor protein p53, which, in turn, can activate the apoptotic cascade (39, 40), we examined the effects of 15⌬PGJ 2 and troglitazone on p53 expression. We found that 15⌬PGJ 2 induced a 4-to 5-fold increase in p53 expression compared to either control cultures or cultures containing troglitazone (Fig. 5B) . Taken together, we conclude that the two PPAR␥ ligands have opposing effects on trophoblasts, with troglitazone promoting differentiation and 15⌬PGJ 2 diminishing differentiation and inducing apoptosis.
Discussion
Intact fetal development depends on placental formation and trophoblast differentiation. The molecular mechanisms that underlie these processes are largely unknown. We found that PPAR␥, a nuclear protein that is essential for proper placental development and trophoblast differentiation in the mouse (21, 22) , is expressed in human placental cytotrophoblast and syncytiotrophoblast, and that the expression and activity of PPAR␥ are associated with trophoblast differentiation. These findings suggest that PPAR␥ may play an important function in the differentiation of human trophoblasts. Importantly, PPAR␥ is a ligand-dependent nuclear receptor. PPAR␥ ligands modulate differentiation (5, 7, 8, 13, (17) (18) (19) (20) and apoptosis (9, 38) in other cell systems. We selected two ligands known to stimulate PPAR␥ activity, namely the thiazolidinedione troglitazone and the prostanoid 15⌬PGJ 2 . Surprisingly, we found that whereas troglitazone stimulates biochemical and morphological differentiation of trophoblasts, 15⌬PGJ 2 hinders differentiation and induces apoptosis. The ability of troglitazone to induce differentiation of human trophoblast, the diminution of hCG production by the PPAR␥ antagonist BADGE, and the disrupted differentiation observed in PPAR␥-deficient mice (21) suggest that an endogenous, troglitazone-like ligand predominates during trophoblast differentiation in vivo. The possibility that PPARs play a role in trophoblast differentiation was first reported by Matsuo and Strauss using the choriocarcinoma cell line JEG-3 (41) . They demonstrated that when ligands for retinoid X receptor, the heterodimer partner of PPARs, were added to cultures of JEG-3 cells, hCG secretion was enhanced. In addition, when ligands for PPAR␣ were added to the cultures, hCG secretion was diminished.
Biochemical and morphological trophoblast differentiation are stimulated by 8-Br-cAMP (25, 33, 42) . Whereas 8-BrcAMP enhances hCG secretion, the intracellular levels of PPAR␥ remain constant throughout the culture period. These results suggest that the stimulus for trophoblast differentiation induces an endogenous ligand for PPAR␥. When trophoblasts were cultured in the presence of both troglitazone and 8-Br-cAMP, an additive increase in hCG secretion was observed compared to that with either substance alone (data not shown), supporting the hypothesis that 8-Br-cAMP induces an endogenous PPAR␥ ligand. Alternatively, because PPAR␥ is inactivated by phosphorylation (43-45), dephosphorylation and subsequent stimulation of PPAR␥ may explain PPAR␥ activation during trophoblast differentiation. Experiments are currently underway to determine whether ligand production is enhanced or the phosphorylation state is altered in trophoblasts exposed to 8-Br-cAMP. Interestingly, when trophoblasts are cultured in H/W medium, which is known to hinder trophoblast differentiation, PPAR␥ expression is diminished. These data are consistent with those presented by Barak et al. (21) , who reported that maturation of the early labyrinthine parenchyma into chorionic villi trophoblast is blocked in mice lacking PPAR␥. Together, it is likely that PPAR␥ activity is essential for trophoblast differentiation.
In contrast to troglitazone, the putative natural PPAR␥ ligand 15⌬PGJ 2 hinders trophoblast differentiation and induces apoptosis. The ability of 15⌬PGJ 2 to induce apoptosis has been documented in monocytes (9) and endothelial cells (38) . In addition, Ikai et al. (46) demonstrated that another PGD 2 derivative, ⌬ 12 -PGJ 2 , increased p53 expression and apoptosis in endothelial cells. Our results are also supported by Clay et al. (37) , who found that 15⌬PGJ 2 , but not troglitazone, stimulated apoptosis in breast cancer cell lines. There are at least two explanations for the disparate effects of troglitazone and 15⌬PGJ 2 on trophoblasts. The first involves ligand-and promoter-specific conformational changes in the protein, which result in altered capacity to physically interact with a distinct set of coregulators, where one coregulator complex stimulates gene expression, and the other represses expression. For example, it is known that the antiestrogen 4-hydroxytamoxifen induces a conformational change in the estrogen receptor (ER) distinct from that induced by estradiol (47, 48) . This conformational change inhibits activation via the ligand-dependent AF-2 domain, thus accounting for the antagonistic effects of 4-hydroxytamoxifen on estrogenmediated ER responses. Studies are currently underway to pursue this possibility. Alternatively, the possibility that one or both PPAR␥ ligands may act independently of PPAR␥, as previously suggested using other cells (49 -52) , cannot be excluded. Experiments using the combination of 15DPGJ 2 and BADGE are unable to resolve this issue because both compounds inhibit hCG secretion in primary trophoblasts. Therefore, when both compounds are added to trophoblast cultures, no increase in hCG secretion is observed (data not shown). Regardless of their mechanism of action, the opposing effects of troglitazone and 15⌬PGJ 2 on trophoblast differentiation may elucidate the processes that govern trophoblast differentiation and apoptosis.
Our data may have profound clinical implications. Dysfunction of the human placenta may result in fetal growth restriction (53, 54) , a condition associated with abnormal trophoblast differentiation and enhanced apoptosis (55) . If, in fact, 15⌬PGJ 2 causes placental trophoblast apoptosis in vivo, it would be intriguing to determine whether 15⌬PGJ 2 levels are increased in conditions such as fetal growth restriction. In this scenario, inhibition of 15⌬PGJ 2 production and stimulation of the troglitazone pathway might reverse the apoptotic pathway and support placental development and differentiation. 
